Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis [5]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 4, 2007, Pages 400-401

  Shim, Joo Cheol ^a   Choe, Byeong Moo ^b   Kim, Jung Gee ^c   Jae, Young Myo ^d   Kim, Ho Chan ^e   Kim, Sung Gon ^f   Oh, Min Kyung ^a   Kelly, Deanna L ^g   Conley, Robert R ^g  

^a Inje University College of Medicine   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c Maryknoll Hospital   (South Korea)

^d Bong Seng Hospital   (South Korea)

^e Kosin University   (South Korea)

^f Pusan National University   (South Korea)

^g UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; KAPLAN MEIER METHOD; LETTER; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HALOPERIDOL; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE;

EID: 34447549043     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000264991.01277.26     Document Type: Letter

References (6)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
2. Fleischhacker WW, Keet IP, KahnRS. EUFEST Steering Committee. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005;78:147-156.
3. Ascher-SvanumH, ZhuB, FariesD, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6:8.
4. McEvoy JP, Schooler NR, Wilson WH. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacol Bull. 1991;27:97-101.
5. Emsley RA, Roberts MC, Rataemane S, et al. Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry. 2002;63:9-14.
6. Jorm AF, Nakane Y, Christensen H, et al. Public beliefs about treatment and outcome of mental disorders: a comparison of Australia and Japan. BMC Med. 2005;3:12.